World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ANZCTR
Last refreshed on: 13 January 2020
Main ID:  ACTRN12610000561088
Date of registration: 12/07/2010
Prospective Registration: No
Primary sponsor: The Woolcock Institute of Medical Research
Public title: How do thick airway walls affect airway hyperresponsiveness in asthma.
Scientific title: Effect in asthmatic subjects of changes in airway wall thickness induced by inhaled corticosteroids on airway hyperresponsiveness
Date of first enrolment: 01/08/2008
Target sample size: 60
Recruitment status: Completed
URL:  https://anzctr.org.au/ACTRN12610000561088.aspx
Study type:  Interventional
Study design:  Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Safety;  
Phase:  Phase 4
Countries of recruitment
Australia
Contacts
Name: Dr Nathan Brown   
Address:  Woolcock Institute of Medical Research 431 Glebe Point Road Glebe NSW 2050 Australia
Telephone: +61 2 9114 0147
Email: njb@woolcock.org.au
Affiliation: 
Name: Dr Nathan Brown   
Address:  Woolcock Institute of Medical Research 431 Glebe Point Road Glebe NSW 2050 Australia
Telephone: +61 2 9114 0147
Email: njb@woolcock.org.au
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: doctor-diagnosed asthma; current symptoms of asthma; airway hyperresponsiveness to methacholine; taking no more than 800ug Beclomethasone diproprionate (BDP) equivalent/day;
Exclusion criteria: current smokers within the last year or having more than 10 years pack history; pregnancy; history of lung cancer, lung reduction surgery, major illness (heart attack, stroke, epilepsy, rheumatoid arthritis); respiratory infection or oral pregnisolone use within the four weeks prior to study participation

Age minimum: 18 Years
Age maximum: No limit
Gender: Both males and females
Health Condition(s) or Problem(s) studied
Asthma;
Asthma
Respiratory - Asthma
Intervention(s)
All subjects will be treated with fluticasone as inhaled combination therapy (Seretide) at 500ug twice daily (bd) for twelve weeks
Primary Outcome(s)
Change in airway wall thickness, measured using high resoution computed tomography (HRCT) scans, during 3 months treatment correlates with a change in airway responsiveness, measured using methacholine bronchial challenge tests.[after 3 months of treatment]
correlation between airway stiffness, measured using the forced oscillation technique, and airway responsiveness, measured using methacholine bronchial challenge tests[before and after 3 months of treatment]
Secondary Outcome(s)
correlation between airway wall thickening, measured using high resoution computed tomography (HRCT) scans, and airway stiffness, measured using the forced oscillation technique.[before and after 3 months of treatment]
Secondary ID(s)
National Health and Medical Research Council (NHMRC) Grant No: X08-0072
Source(s) of Monetary Support
NHMRC
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date:
Contact:
Sydney South West Area Health Service
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history